SCHEMBL5542591

SCHEMBL5542591

[CH2]c1ccc(Oc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.52
KIF11 P52732 1/20 0.49
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
AR P10275 1/20 0.47
ESR2 Q92731 1/20 0.47
TLR8 Q9NR97 1/20 0.46
TLR7 Q9NYK1 1/20 0.46
TTBK1 Q5TCY1 2/20 0.45
TEAD1 P28347 1/20 0.45
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
SCN9A Q15858 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPK14 Q16539 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27579381 0.91 LTA4H (0.59) LTA4HKIF11NR3C1PGRAR
SCHEMBL6746131 0.87 KIF11 (0.50) LTA4HKIF11NR3C1PGRAR
SCHEMBL9798371 0.87 LTA4H (0.54) LTA4HKIF11NR3C1PGRAR
SCHEMBL9546526 0.85 L3MBTL1 (0.55) LTA4HKIF11NR3C1PGRAR
SCHEMBL13809396 0.82 LTA4H (0.52) LTA4HKIF11NR3C1PGRAR
SCHEMBL15635197 0.82 PPARG (0.55) LTA4HKIF11NR3C1PGRAR
SCHEMBL4043144 0.82 LTA4H (0.53) LTA4HKIF11NR3C1PGRAR
SCHEMBL5541954 0.82 KIF11 (0.46) LTA4HKIF11NR3C1PGRAR
SCHEMBL3553556 0.82 LTA4H (0.52) LTA4HKIF11NR3C1PGRAR
SCHEMBL9589615 0.82 LTA4H (0.53) LTA4HKIF11NR3C1PGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LTA4H 3452/4885KIF11 3946/4885NR3C1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.